Shire announces publication of open-label study on coadministration of INTUNIV with stimulants

PHILADELPHIA -- November 16, 2009 -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV? (guanfacine) Extended-Release Tablets published in the October Journal of Child and Adolescent Psychopharmacology.

Read the whole article on Science Blog

More from Science Blog